{"id":"placebo-ophthalmic-solution","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it is designed to mimic the appearance and feel of a real medication, but without any actual pharmacological activity. This allows researchers to compare the effects of the real treatment to a control group, helping to establish the efficacy of the actual medication.","oneSentence":"This is a placebo ophthalmic solution, meaning it has no active therapeutic effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:36.404Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of dry eye syndrome"}]},"trialDetails":[{"nctId":"NCT07495852","phase":"PHASE3","title":"Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2026-02-17","conditions":"Glaucoma","enrollment":510},{"nctId":"NCT06854393","phase":"PHASE2","title":"Lacripep for Corneal Wound Healing Study","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2025-05-23","conditions":"Corneal Epithelial Wound Healing","enrollment":88},{"nctId":"NCT04149210","phase":"PHASE3","title":"FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2021-08-19","conditions":"Trachomatous Trichiasis (TT), Eye Diseases, Eyelid Diseases","enrollment":2410},{"nctId":"NCT07490535","phase":"PHASE4","title":"This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"Pittsburgh Research Institute","startDate":"2026-03","conditions":"Ocular Surface Disease, Dry Eye Syndrome (DES)","enrollment":36},{"nctId":"NCT05795699","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2023-03-30","conditions":"Fuchs Endothelial Corneal Dystrophy","enrollment":107},{"nctId":"NCT05733572","phase":"PHASE2","title":"Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Benedetto Falsini","startDate":"2023-06-12","conditions":"Optic Pathway Glioma","enrollment":36},{"nctId":"NCT06089317","phase":"NA","title":"Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2024-07-28","conditions":"Dry Eye Syndromes","enrollment":200},{"nctId":"NCT06911424","phase":"PHASE3","title":"Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis","status":"RECRUITING","sponsor":"Baxis Pharmaceuticals, Inc.","startDate":"2025-03-21","conditions":"Bacterial Conjunctivitis","enrollment":400},{"nctId":"NCT06792903","phase":"EARLY_PHASE1","title":"YM-101 Eye Drops in the Treatment of Dry Eye Syndrome","status":"COMPLETED","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2024-04-23","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT06542497","phase":"PHASE3","title":"Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2024-08-15","conditions":"Presbyopia","enrollment":569},{"nctId":"NCT05646719","phase":"PHASE3","title":"Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2022-12-22","conditions":"Presbyopia","enrollment":333},{"nctId":"NCT06349759","phase":"PHASE3","title":"Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2024-04-01","conditions":"Mesopic Vision, Night Vision Loss","enrollment":200},{"nctId":"NCT07449000","phase":"NA","title":"Losartan for Corneal Fibrosis","status":"RECRUITING","sponsor":"Universidad Autonoma de Nuevo Leon","startDate":"2026-02-12","conditions":"Corneal Scarring Fibrosis","enrollment":46},{"nctId":"NCT07095894","phase":"PHASE3","title":"A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control","status":"NOT_YET_RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2026-03-01","conditions":"Myopia","enrollment":348},{"nctId":"NCT04923841","phase":"NA","title":"Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2021-09-09","conditions":"Myopia","enrollment":579},{"nctId":"NCT07075718","phase":"PHASE2, PHASE3","title":"Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2025-06-12","conditions":"Glaucoma","enrollment":610},{"nctId":"NCT05532124","phase":"PHASE2","title":"Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.","status":"COMPLETED","sponsor":"Green Cross Wellbeing","startDate":"2021-06-01","conditions":"Chronic Liver Disease","enrollment":49},{"nctId":"NCT03601247","phase":"NA","title":"Silicone Gel for Postsurgical Scars of the Eyelid","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2018-08-01","conditions":"Scarring Due to Treatment","enrollment":132},{"nctId":"NCT06244316","phase":"PHASE2","title":"A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2024-01-22","conditions":"Dry Eye Disease","enrollment":317},{"nctId":"NCT07264517","phase":"PHASE2","title":"Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).","status":"RECRUITING","sponsor":"Instituto Grifols, S.A.","startDate":"2025-11-03","conditions":"Dry Eye Disease","enrollment":100},{"nctId":"NCT07028827","phase":"PHASE3","title":"Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)","status":"RECRUITING","sponsor":"Ocus Innovation Ireland Limited","startDate":"2025-09-01","conditions":"Myopia","enrollment":234},{"nctId":"NCT06780306","phase":"PHASE2","title":"A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.","status":"COMPLETED","sponsor":"BioTissue Holdings, Inc","startDate":"2024-12-12","conditions":"Dry Eye, Dry Eye Disease (DED), Dry Eye Disease With Severe Keratitis","enrollment":74},{"nctId":"NCT07400952","phase":"PHASE2","title":"Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2025-12-23","conditions":"Keratoconus","enrollment":100},{"nctId":"NCT07384767","phase":"PHASE2","title":"Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing","status":"NOT_YET_RECRUITING","sponsor":"University of California, Davis","startDate":"2026-06-01","conditions":"Mohs Micrographic Surgery, Excision Margin","enrollment":220},{"nctId":"NCT06659549","phase":"PHASE2","title":"A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD","status":"RECRUITING","sponsor":"Galimedix Therapeutics Inc","startDate":"2025-01-10","conditions":"Geographic Atrophy of the Macula","enrollment":110},{"nctId":"NCT07382453","phase":"PHASE2","title":"Effect of PAE Hydrogel Loaded With tRF-ASO-Exo on Patients With Diabetic Ocular Surface Diseases","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2026-02-15","conditions":"Diabetic Keratopathy","enrollment":30},{"nctId":"NCT06852768","phase":"PHASE1, PHASE2","title":"Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)","status":"RECRUITING","sponsor":"Regenerative Ocular Immunobiologics LLC","startDate":"2025-01-10","conditions":"oGHVD","enrollment":1},{"nctId":"NCT05110001","phase":"PHASE3","title":"Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2022-08-03","conditions":"Acanthamoeba Keratitis, Fungal Keratitis","enrollment":330},{"nctId":"NCT01471184","phase":"NA","title":"The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo","status":"COMPLETED","sponsor":"Bitop AG","startDate":"2009-09","conditions":"Allergic Rhinitis, Allergic Conjunctivitis","enrollment":46},{"nctId":"NCT07369375","phase":"NA","title":"Efficacy and Safety of VMX Eye Drops for Dry Eye Disease","status":"NOT_YET_RECRUITING","sponsor":"VISUfarma SpA","startDate":"2026-02-02","conditions":"Dry Eye Disease (DED)","enrollment":76},{"nctId":"NCT06213649","phase":"PHASE3","title":"Parasitic Ulcer Treatment Trial","status":"RECRUITING","sponsor":"Jeremy Keenan, MD, MPH","startDate":"2024-07-01","conditions":"Acanthamoeba Keratitis","enrollment":232},{"nctId":"NCT07227883","phase":"EARLY_PHASE1","title":"Secretome Treatment for Facial Rejuvenation","status":"RECRUITING","sponsor":"Acorn Biolabs Inc.","startDate":"2025-12-15","conditions":"Facial Aging, Rejuvenation, Stem Cell","enrollment":24},{"nctId":"NCT07364370","phase":"NA","title":"Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-02","conditions":"Pediatric Cataract, IOL Implantation, Myopia Progression","enrollment":50},{"nctId":"NCT05826353","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2023-05-11","conditions":"Fuchs Endothelial Corneal Dystrophy","enrollment":110},{"nctId":"NCT04505566","phase":"PHASE1","title":"INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stephen J. Kim, MD","startDate":"2020-11-09","conditions":"Diabetic Retinopathy","enrollment":164},{"nctId":"NCT05411367","phase":"PHASE3","title":"A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye","status":"COMPLETED","sponsor":"Seikagaku Corporation","startDate":"2022-07-28","conditions":"Dry Eye Disease","enrollment":232},{"nctId":"NCT05002998","phase":"PHASE4","title":"TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-09-16","conditions":"Thyroid Eye Disease","enrollment":313},{"nctId":"NCT03918915","phase":"PHASE3","title":"The Safety and Efficacy of SYD-101 in Children With Myopia","status":"COMPLETED","sponsor":"Sydnexis, Inc.","startDate":"2019-04-24","conditions":"Nearsightedness, Near Sightedness, Near-sightedness","enrollment":852},{"nctId":"NCT06144918","phase":"PHASE2","title":"Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure","status":"COMPLETED","sponsor":"Skye Bioscience, Inc.","startDate":"2023-11-09","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":56},{"nctId":"NCT05066997","phase":"PHASE2, PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2021-10-19","conditions":"Diabetic Macular Edema","enrollment":552},{"nctId":"NCT06172257","phase":"PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2024-03-15","conditions":"Diabetic Macular Edema","enrollment":401},{"nctId":"NCT07329777","phase":"PHASE3","title":"Atropine in the Treatment of Myopia Study in Malaysia","status":"RECRUITING","sponsor":"IDB VisionCare SDN BHD","startDate":"2025-09-17","conditions":"Myopia Progression","enrollment":144},{"nctId":"NCT07313722","phase":"PHASE1","title":"Study Evaluating Safety of BT01001 Ophthalmic Solution","status":"RECRUITING","sponsor":"Beyang Therapeutics Co., Ltd.","startDate":"2025-11-17","conditions":"Healthy","enrollment":32},{"nctId":"NCT04928391","phase":"PHASE3","title":"A Single Bolus of Dexmedetomidine Versus Normal Saline in Postoperative Agitation","status":"RECRUITING","sponsor":"Assiut University","startDate":"2021-06-20","conditions":"Cleft Palate","enrollment":60},{"nctId":"NCT07305987","phase":"PHASE3","title":"PRO-232 in Patients Subjected to Cataract Surgery","status":"RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-10-27","conditions":"Cataract Extraction","enrollment":134},{"nctId":"NCT05555589","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2","status":"RECRUITING","sponsor":"ReGenTree, LLC","startDate":"2023-04-11","conditions":"Neurotrophic Keratopathy","enrollment":70},{"nctId":"NCT07245017","phase":"EARLY_PHASE1","title":"JN002 for the Treatment of Dry Eye Disease","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-11-24","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT04735393","phase":"PHASE3","title":"A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2021-01-26","conditions":"Dry Eye Disease","enrollment":757},{"nctId":"NCT05136170","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-01-27","conditions":"Dry Eye Disease","enrollment":85},{"nctId":"NCT06717152","phase":"PHASE3","title":"Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd.","startDate":"2024-12-30","conditions":"Dry Eye","enrollment":427},{"nctId":"NCT07220408","phase":"PHASE2","title":"Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis","status":"RECRUITING","sponsor":"Telios Pharma, Inc.","startDate":"2025-10-23","conditions":"Allergic Conjunctivitis","enrollment":60},{"nctId":"NCT06441643","phase":"PHASE2","title":"Next Generation Rocklatan","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-09-04","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":426},{"nctId":"NCT06628947","phase":"PHASE2","title":"A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa","status":"RECRUITING","sponsor":"Kiora Pharmaceuticals, Inc.","startDate":"2025-08-29","conditions":"Retinitis Pigmentosa","enrollment":36},{"nctId":"NCT04968912","phase":"PHASE2","title":"A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-21","conditions":"Sjogren's Syndrome","enrollment":163},{"nctId":"NCT04638660","phase":"PHASE3","title":"Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2020-12-30","conditions":"Dim Light Vision Disturbances","enrollment":144},{"nctId":"NCT04675151","phase":"PHASE2","title":"Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2021-02-15","conditions":"Presbyopia","enrollment":150},{"nctId":"NCT06658002","phase":"PHASE3","title":"Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-09-01","conditions":"Fungal Keratitis, Corneal Ulcer","enrollment":150},{"nctId":"NCT07140783","phase":"PHASE3","title":"OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity","status":"RECRUITING","sponsor":"Ocuphire Pharma, Inc.","startDate":"2025-09-02","conditions":"Vision Loss Night, Vision Disorders","enrollment":200},{"nctId":"NCT04440280","phase":"PHASE2","title":"Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2020-09-16","conditions":"Fuchs Endothelial Corneal Dystrophy","enrollment":45},{"nctId":"NCT05340881","phase":"NA","title":"Systematic Light Exposure in Pediatric Brain Tumor Survivors","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2022-10-14","conditions":"Brain Tumor","enrollment":40},{"nctId":"NCT07179055","phase":"PHASE2","title":"An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye","status":"RECRUITING","sponsor":"Vanda Pharmaceuticals","startDate":"2025-10","conditions":"Dry Eye","enrollment":160},{"nctId":"NCT07109609","phase":"PHASE2","title":"Topical Menthol For Tear Secretion","status":"ENROLLING_BY_INVITATION","sponsor":"Reinhold Vieth","startDate":"2025-08-17","conditions":"Healthy, Dry Eyes","enrollment":30},{"nctId":"NCT04622345","phase":"PHASE2","title":"Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies","status":"COMPLETED","sponsor":"Vanda Pharmaceuticals","startDate":"2020-11-21","conditions":"Allergic Conjunctivitis","enrollment":47},{"nctId":"NCT04130802","phase":"PHASE2","title":"OCS-01 in Treating Inflammation and Pain in Post-cataract Patients","status":"COMPLETED","sponsor":"Oculis","startDate":"2019-09-27","conditions":"Inflammation Corneal, Pain, Postoperative","enrollment":153},{"nctId":"NCT07162818","phase":"PHASE4","title":"Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2021-04-28","conditions":"Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment","enrollment":61},{"nctId":"NCT06969001","phase":"PHASE1","title":"Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops","status":"COMPLETED","sponsor":"SCAI Therapeutics","startDate":"2025-05-29","conditions":"Wet Age Related Macular Degeneration","enrollment":48},{"nctId":"NCT07164092","phase":"PHASE2, PHASE3","title":"Efficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-09","conditions":"Myopia","enrollment":45},{"nctId":"NCT06523504","phase":"PHASE1, PHASE2","title":"Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control","status":"RECRUITING","sponsor":"Ruihua Wei","startDate":"2024-02-01","conditions":"Myopia","enrollment":410},{"nctId":"NCT05938699","phase":"PHASE2, PHASE3","title":"Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2023-12-12","conditions":"Open Angle Glaucoma","enrollment":18},{"nctId":"NCT07154147","phase":"PHASE4","title":"Oral vs IV Sedation for Cataract Surgery in Older Adults","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-08-12","conditions":"Cataract Surgery, Sedation, Cognition Function","enrollment":20},{"nctId":"NCT05913232","phase":"PHASE2","title":"Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"D. Western Therapeutics Institute, Inc.","startDate":"2023-08-28","conditions":"Glaucoma Open-Angle Primary, Ocular Hypertension","enrollment":201},{"nctId":"NCT03293524","phase":"PHASE3","title":"Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year","status":"COMPLETED","sponsor":"GenSight Biologics","startDate":"2018-03-12","conditions":"Leber Hereditary Optic Neuropathy","enrollment":98},{"nctId":"NCT05145361","phase":"EARLY_PHASE1","title":"Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2022-04-07","conditions":"NMO Spectrum Disorder","enrollment":45},{"nctId":"NCT06637527","phase":"PHASE2","title":"The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain","status":"TERMINATED","sponsor":"Okyo Pharma Ltd","startDate":"2024-10-15","conditions":"Neuropathic Pain","enrollment":18},{"nctId":"NCT07124143","phase":"NA","title":"The Effect of Platelet-Rich Plasma on Wound Healing After Gingivectomy","status":"COMPLETED","sponsor":"Duygu Kilic","startDate":"2021-06-02","conditions":"Gingival Overgrowth","enrollment":38},{"nctId":"NCT07120308","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects Caused by Neurotrophic Keratitis","status":"COMPLETED","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2021-09-15","conditions":"Corneal Epithelial Defect","enrollment":28},{"nctId":"NCT02484716","phase":"PHASE2","title":"Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-06","conditions":"Telangiectasia, Hereditary Hemorrhagic, Osler Rendu Disease","enrollment":58},{"nctId":"NCT06209281","phase":"PHASE3","title":"A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2022-05-13","conditions":"Myopia","enrollment":526},{"nctId":"NCT06209320","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2022-03-15","conditions":"Myopia","enrollment":777},{"nctId":"NCT07068958","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"ORA, Inc.","startDate":"2025-08-01","conditions":"Dry Eye Disease (DED)","enrollment":200},{"nctId":"NCT06352541","phase":"PHASE1","title":"Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.","status":"NOT_YET_RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-09-30","conditions":"Healthy","enrollment":28},{"nctId":"NCT06975748","phase":"PHASE2","title":"A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis","status":"RECRUITING","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2025-06-12","conditions":"Neurotrophic Keratitis","enrollment":48},{"nctId":"NCT06865144","phase":"PHASE4","title":"Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT","status":"RECRUITING","sponsor":"East Coast Institute for Research","startDate":"2025-06-27","conditions":"Primary Open Angle Glaucoma or Ocular Hypertension","enrollment":70},{"nctId":"NCT03911271","phase":"PHASE2","title":"Low-dose Atropine for the Prevention of Myopia Progression in Danish Children","status":"COMPLETED","sponsor":"Line Kessel","startDate":"2019-05-30","conditions":"Myopia","enrollment":97},{"nctId":"NCT06818487","phase":"NA","title":"Ganyan-1 in Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2025-07-01","conditions":"Dry Eye, TCM","enrollment":219},{"nctId":"NCT07012512","phase":"NA","title":"Adjusted Study Protocol: Within-Subject Paired-Eye Design Comparing Pilocarpine 0.1%, Phentolamine 0.75%, and Combination Therapy for Cyclopentolate Reversal in Children","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-06-01","conditions":"Pupillary Constriction, Accomodation","enrollment":60},{"nctId":"NCT06363487","phase":"NA","title":"Semaglutide and Cognition in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2024-06-06","conditions":"Cognitive Change","enrollment":70},{"nctId":"NCT04734210","phase":"PHASE2","title":"Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2021-01-07","conditions":"Dry Eye Disease","enrollment":139},{"nctId":"NCT05608837","phase":"PHASE2","title":"Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Quan Dong Nguyen","startDate":"2023-05-26","conditions":"Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative","enrollment":28},{"nctId":"NCT06960629","phase":"","title":"The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)","status":"ENROLLING_BY_INVITATION","sponsor":"University Hospital Dubrava","startDate":"2025-04-01","conditions":"Pseudophakic Bullous Keratopathy, Glaucoma","enrollment":50},{"nctId":"NCT04030962","phase":"PHASE1, PHASE2","title":"A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-03-04","conditions":"Dry Eye Disease, Dry Eye Syndrome","enrollment":292},{"nctId":"NCT04818203","phase":"PHASE1, PHASE2","title":"A Study on the Anti-Wrinkle Efficacy Assessment and Safety Evaluation of the Cluster of Autologous Dermal Fibroblast on Bilateral Crow's Feet","status":"RECRUITING","sponsor":"S.Biomedics Co., Ltd.","startDate":"2020-07-20","conditions":"Crow's Feet","enrollment":80},{"nctId":"NCT06969586","phase":"","title":"The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy","status":"ENROLLING_BY_INVITATION","sponsor":"University Hospital Dubrava","startDate":"2025-04-01","conditions":"Fuchs Endothelial Corneal Dystrophy, Cataract, Glaucoma","enrollment":50},{"nctId":"NCT04734197","phase":"PHASE2","title":"A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2021-01-11","conditions":"Dry Eye Disease","enrollment":349},{"nctId":"NCT04565756","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Tolerability of EXN407","status":"COMPLETED","sponsor":"Exonate Limited","startDate":"2020-11-05","conditions":"Diabetic Macular Edema","enrollment":48},{"nctId":"NCT06956846","phase":"PHASE4","title":"Efficacy of Topical Insuline in Corneal Epithelial Healing Post PRK","status":"NOT_YET_RECRUITING","sponsor":"Hotel Dieu de France Hospital","startDate":"2025-04-25","conditions":"Corneal Epithelial Wound Healing","enrollment":100},{"nctId":"NCT06100939","phase":"PHASE3","title":"Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Epion Therapeutics","startDate":"2023-10-30","conditions":"Keratoconus","enrollment":400},{"nctId":"NCT06948357","phase":"PHASE2","title":"Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients","status":"RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2025-03-24","conditions":"Presbyopia","enrollment":119},{"nctId":"NCT05992922","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants","status":"TERMINATED","sponsor":"Iacta Pharmaceuticals","startDate":"2023-10-17","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT03733899","phase":"NA","title":"An Investigation of the Impact of Localized Topical Anesthesia of the Ocular Surface on End-of-day Contact Lens Discomfort","status":"COMPLETED","sponsor":"Johnson & Johnson Vision Care, Inc.","startDate":"2018-11-07","conditions":"Visual Acuity","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["placebo","Vehicle","artificial tears","Inactive control (vehicle)","Matching placebo"],"phase":"phase_3","status":"active","brandName":"Placebo Ophthalmic Solution","genericName":"Placebo Ophthalmic Solution","companyName":"ORA, Inc.","companyId":"ora-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo ophthalmic solution, meaning it has no active therapeutic effect. Used for Treatment of dry eye syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}